Acquisitions
Astromech Buys Form Bio to Combine Evolutionary AI and Genomic Design

Key PointsAstromech paid $230 million in stock to pair its evolutionary modeling with Form Bio's…
View more
- Astromech paid $230 million in stock to pair its evolutionary modeling with Form Bio's genetic-medicine design tools.
- Form Bio's promoter and nuclease work raised AAV full-genome content from 13% to 59% in a Duchenne candidate.
- The open question is whether Astromech's unfinished evolutionary AI can measurably improve Form Bio's reported design results.
Astromech announced on November 17, 2026 that it had acquired Form Bio in an all-stock transaction valued at $230 million, adding the genetic-medicine design company’s intellectual property, selected contracts and assets, and team.
The deal pairs Astromech’s evolutionary modeling with Form Bio’s AI tools for designing genetic medicines, optimizing gene-therapy vectors and manufacturing, and assessing genomic quality. The companies’ stated goal is to help researchers move from identifying evolutionary patterns to designing and testing genetic constructs across human therapeutics, genome engineering and animal health.
Form Bio co-founder and former CEO Andrew Busey has been named Astromech’s Chief AI Officer and Head of Technology. He described Form Bio’s path from computational work on de-extinction to foundation models for designing human therapeutics. “Joining Astromech gives us the opportunity to build on that progress, bringing evolutionary insights into the design decisions we help researchers make,” Busey said.
Evolutionary Modeling Meets Genetic-Medicine Design
Astromech’s technical description presents its Large Life Model as a system still in development. It is being designed to learn across species and evolutionary time, combining attention-based deep learning with Bayesian reconstruction of ancestral sequences and regulatory states. Its listed architecture also includes a graph-based pangenome, which captures structural genetic variants across populations, and a multi-omics integrator, also in development, for unified biological insight across complex systems.
Form Bio brings applied design and manufacturing tools. Its product materials describe FormSightAI screening thousands of vector designs in silico, or computationally, to identify candidates intended to improve yield and reduce contaminants. FormManufacturing supports work from design through commercial release, while FormBatchQC provides lot-level analysis of contaminants and comparability.
By connecting evolutionary insights with those tools, the companies aim to address quality challenges earlier in development, reducing unwanted components during design and potentially lessening the need for downstream purification.
Reported Design Gains and Research Programs
Form Bio’s October 6, 2025 announcement of a partnership with Cure Rare Disease reported that promoter modification and nuclease optimization raised AAV full-genome content in a Duchenne muscular dystrophy candidate from 13% to 59% within one month. The work combined long-read sequencing, genome-integrity analysis, rational design, and AI and machine-learning models.
Full-genome content refers to the proportion of capsids containing a full vector genome, a critical quality attribute for regulatory approval. Cure Rare Disease said the work advanced the program to preclinical studies in living organisms. The result concerns vector-manufacturing quality and preclinical progress, rather than clinical outcomes in patients.
The acquisition announcement also reports that coding-sequence optimization alone increased full-genome content from about 2% to about 45% in a separate program, with expression held at baseline. The two examples used distinct design levers: the Duchenne work changed the promoter and nuclease, while the other changed only the coding sequence.
Form Bio’s capabilities support genetic-medicine programs at Eli Lilly, Stanford, Coave Therapeutics, Taysha Gene Therapies and Solid Biosciences, according to the acquisition announcement.
Shared Colossal Biosciences Roots
Both companies have roots in Colossal Biosciences. Form Bio was developed within Colossal and launched as a spinout in September 2022, later expanding from multi-species genome engineering into human genetic medicines. Astromech emerged from Colossal’s comparative-genomics, ancient-DNA and computational-biology work and was co-founded by George Church and Ben Lamm. The announcement reports more than $40 million in venture financing for Form Bio and more than $60 million for Astromech.
The acquisition puts Form Bio’s applied design tools and external program experience alongside an evolutionary-AI system that remains under construction. The central technical question is whether Astromech’s evolutionary reconstruction can add measurable improvements to the construct-design and manufacturing results Form Bio already reports.












